You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 138 No. 9, September 1984 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Clinical Trial of a New Trivalent Measles-Mumps-Rubella Vaccine in Young Children

Timo Vesikari, MD; Eija-Liisa Ala-Laurila, MD; Anneli Heikkinen, MD; Annikki Terho, MD; Eric D'Hondt, MSc; Francis E. André, MD

Am J Dis Child. 1984;138(9):843-847.


Abstract

• Trivalent measles-mumps-rubella virus vaccines, containing either Schwarz (two dosage levels), Urabe Am 9, and RA 27/3 strains or Moraten, Jeryl Lynn, and RA 27/3 strains, were evaluated in 174 children aged 14 to 24 months. Each of the three vaccines induced a nearly 100% seroconversion for measles and mumps and a full 100% seroconversion for rubella. Close home monitoring disclosed a high incidence and a relatively constant pattern of vaccine-associated reactions, similar for all three vaccines. Febrile reactions of greater than or equal to 39 °C between days 5 and 12 after vaccination were more frequent among the recipients of "high"-dose Schwarz strain vaccine (35%) than among the recipients of corresponding "low"-dose vaccine (23%) or the Moraten strain vaccine (13%). The Schwarz-Urabe Am 9-RA 27/3 was equally immunogenic and, with a low dose of measles virus, no more reactogenic than the Moraten-Jeryl Lynn RA 27/3 trivalent vaccine.

(AJDC 1984;138:843-847)



Author Affiliations

From the Department of Clinical Sciences, University of Tampere (Dr Vesikari), the Health Care Center of the City of Tampere (Drs Ala-Laurila, Heikkinen, and Terho), Tampere, Finland, and the Biological Division, Smith Kline RIT, Rixensart, Belgium (Mr D'Hondt and Dr André).


Footnotes

Reprint requests to Department of Clinical Sciences, University of Tampere, 33520 Tampere 52, Finland (Dr Vesikari).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Day-to-Day Reactogenicity and the Healthy Vaccinee Effect of Measles-Mumps-Rubella Vaccination
Virtanen et al.
Pediatrics 2000;106:62e-62.
ABSTRACT | FULL TEXT  

The Elimination of Indigenous Measles, Mumps, and Rubella from Finland by a 12-Year, Two-Dose Vaccination Program
Peltola et al.
NEJM 1994;331:1397-1402.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1984 American Medical Association. All Rights Reserved.